Evidence map›Paper›PMID 41459482›Full record

Trial reportFrontiers in immunology2025

Long-term compromised immune regulation after rituximab induction in blood group incompatible (ABOi) living-donor renal transplantation - 5 year results of a prospective pilot study.

Rolf Weimer, Hristos Karakizlis, Fabrice Renner, Hartmut Dietrich, Volker Daniel, Caner Süsal, Christian Schüttler, Daniel Kämper, Dominik Leicht, Michael Wörlen and 8 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01136395 (Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation - a Prospective Pilot Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01136395 phase2completednot on this map

Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation - a Prospective Pilot Study

TypeinterventionalSponsorUniversity of GiessenRan2010 to 2019Enrolled85ConditionsKidney Transplantation, Rituximab (RTx), Living Donors, ImmunologyArmsRituximab, living donor transplantation, deceased donor transplantation
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rolf WeimerDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Hristos KarakizlisDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Fabrice RennerDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Hartmut DietrichDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Volker DanielInstitute of Immunology, University of Heidelberg, Heidelberg, Germany.
Caner SüsalInstitute of Immunology, University of Heidelberg, Heidelberg, Germany.
Christian SchüttlerInstitute of Medical Virology, University of Giessen, Giessen, Germany.
Daniel KämperDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Dominik LeichtDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Michael WörlenDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Katrin MilchsackDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Lene RennerDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Maximilian StichDepartment of Internal Medicine, University of Giessen, Giessen, Germany.
Hermann-Josef GröneMedical Faculty, University of Heidelberg, Heidelberg, Germany.
Andreas HeckerDepartment of Surgery, University of Giessen, Giessen, Germany.
Rüdiger HörbeltDepartment of Surgery, University of Giessen, Giessen, Germany.
Winfried PadbergDepartment of Surgery, University of Giessen, Giessen, Germany.
Gerhard OpelzInstitute of Immunology, University of Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: An increased risk of severe infectious disease and acute antibody-mediated rejection (AMR) has been described after ABOi renal transplantation. We performed a prospective renal transplant study up to 5 years posttransplant to detect long-term immunological effects of rituximab administration. Methods: Mononuclear cell subsets in peripheral blood, regional lymph nodes and protocol biopsies, Results: An increased frequency of severe infectious diseases in ABOi recipients (doubled versus ABOc within 2 years, P = 0.042) coincided with profoundly downregulated peripheral blood B cell subsets for at least 2 years, impaired Conclusions: An increased frequency of severe infectious diseases in ABOi renal transplant recipients may be explained by rituximab-induced long-term immunological effects on CD4+ and CD8+ T cell counts and the prolonged depletion of B cell subsets together with compromised B cell responses. In protocol graft biopsies, rituximab induced early B cell depletion but counter-regulatory proinflammatory effects coinciding with an increased acute rejection frequency. Registration Details: ClinicalTrials.gov, identifier NCT01136395; EudraCT, identifier No.: 2009-012198-36.

Indexed as

ABO Blood-Group SystemBlood Group IncompatibilityKidney TransplantationRituximabAdultB-LymphocytesFemaleGraft RejectionHumansLiving DonorsMaleMiddle AgedPilot ProjectsProspective StudiesABO Blood-Group SystemRituximabABO incompatibleacute rejectionB cell repopulationHLA antibodieskidney transplantationprotocol biopsiesrituximabsevere infectious disease

Identifiers

PMID41459482
PMCPMC12740749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.